Alkermes plc. Financial Summary

Quick Answer

Alkermes plc. reported Total Revenue of $1.48 billion for fiscal year 2025.

Alkermes plc. — Key Financials by Year

Metric 2025 2024 2023 2022 2021 2020
Total Revenue $1.48B
-5.2%
$1.56B
-6.4%
$1.66B
+49.6%
$1.11B
-5.3%
$1.17B
+13.0%
$1.04B
-11.3%
Revenue (ASC 606) $1.48B
-5.2%
$1.56B
-6.4%
$1.66B
+49.6%
$1.11B
-5.3%
$1.17B
+13.0%
$1.04B
-11.3%
Net Income $241.66M
-34.2%
$367.07M
+3.2%
$355.76M
+324.8%
-$158.27M
-228.6%
-$48.17M
+56.6%
-$110.86M
+43.6%
Diluted EPS $1.43
-34.1%
$2.17
+3.3%
$2.10
+316.5%
-$0.97
-234.5%
-$0.29
+58.6%
-$0.70
Total Assets $2.49B
+21.0%
$2.06B
-3.8%
$2.14B
+8.8%
$1.96B
-3.0%
$2.02B
+3.8%
$1.95B
+8.0%
Cash and Equivalents $388.57M
+33.5%
$291.15M
-36.4%
$457.47M
+56.4%
$292.47M
-13.4%
$337.54M
+23.7%
$272.96M
+34.0%
Long-Term Debt $287.73M
-0.9%
$290.27M
-0.9%
$292.80M
+7.6%
$272.12M
-0.8%
Stockholders Equity $1.82B
+24.2%
$1.46B
+21.8%
$1.20B
+15.2%
$1.04B
-6.2%
$1.11B
+4.3%
$1.07B
-1.7%
R&D Expense $323.96M
+32.1%
$245.33M
-9.4%
$270.81M
-0.7%
$272.70M
-6.3%
$290.92M
-26.3%
$394.59M
-23.1%
Operating Income $253.96M
-39.6%
$420.64M
+1.6%
$414.12M
+6901.1%
-$6.09M
-106.2%
$97.75M
+186.9%
-$112.43M
+35.9%
Shares Outstanding 165.61M
+2.1%
162.18M
-2.9%
166.98M
+1.6%
164.38M
+1.5%
161.94M
+1.7%
159.16M
+0.9%

Most Recent Quarter

Metric Quarter Ending Value YoY QoQ
Total Revenue September 30, 2025 $394.19M +4.2% +0.9%
Revenue (ASC 606) September 30, 2025 $394.19M +4.2% +0.9%
Net Income September 30, 2025 $82.76M -10.4% -5.0%
Diluted EPS September 30, 2025 $0.49 -10.9% -5.8%
Total Assets September 30, 2025 $2.33B +8.1% +3.4%
Cash and Equivalents September 30, 2025 $616.45M +55.6% +18.3%
Long-Term Debt September 30, 2024 $285.82M -0.9% -0.2%
Stockholders Equity September 30, 2025 $1.73B +34.2% +6.7%
R&D Expense September 30, 2025 $81.74M +36.5% +5.6%
Operating Income September 30, 2025 $89.08M -15.0% -4.2%
Shares Outstanding September 30, 2025 165.10M +2.1% +0.0%
  • Alkermes plc. reported Total Revenue of $1.48 billion for fiscal year 2025.
  • Alkermes plc. showed a decrease of -5.2% in Total Revenue compared to the prior fiscal year.
  • Alkermes plc. reported Revenue (ASC 606) of $1.48 billion for fiscal year 2025.
  • Alkermes plc. showed a decrease of -5.2% in Revenue (ASC 606) compared to the prior fiscal year.
  • Alkermes plc. reported Net Income of $241.66 million for fiscal year 2025.
  • Alkermes plc. showed a decrease of -34.2% in Net Income compared to the prior fiscal year.
  • Alkermes plc. reported Diluted EPS of $1.43 per share for fiscal year 2025.
  • Alkermes plc. showed a decrease of -34.1% in Diluted EPS compared to the prior fiscal year.
  • Alkermes plc. reported Total Assets of $2.49 billion for fiscal year 2025.
  • Alkermes plc. showed an increase of +21.0% in Total Assets compared to the prior fiscal year.
  • Alkermes plc. reported Cash and Equivalents of $388.57 million for fiscal year 2025.
  • Alkermes plc. showed an increase of +33.5% in Cash and Equivalents compared to the prior fiscal year.
  • Alkermes plc. reported Long-Term Debt of $287.73 million for fiscal year 2023.
  • Alkermes plc. showed a decrease of -0.9% in Long-Term Debt compared to the prior fiscal year.
  • Alkermes plc. reported Stockholders Equity of $1.82 billion for fiscal year 2025.
  • Alkermes plc. showed an increase of +24.2% in Stockholders Equity compared to the prior fiscal year.
  • Alkermes plc. reported R&D Expense of $323.96 million for fiscal year 2025.
  • Alkermes plc. showed an increase of +32.1% in R&D Expense compared to the prior fiscal year.
  • Alkermes plc. reported Operating Income of $253.96 million for fiscal year 2025.
  • Alkermes plc. showed a decrease of -39.6% in Operating Income compared to the prior fiscal year.
  • Alkermes plc. reported Shares Outstanding of 165.61 million shares for fiscal year 2025.
  • Alkermes plc. showed an increase of +2.1% in Shares Outstanding compared to the prior fiscal year.
  • All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.

Last verified:

Leave a Comment